Glyscend taps CEO to lead oral obe­si­ty, type 2 di­a­betes can­di­date; Ex-Travec­ta chief bounces back af­ter com­pa­ny shut­down

As a new wave of type 2 di­a­betes and obe­si­ty drugs takes the in­dus­try by storm, Glyscend Ther­a­peu­tics has tapped a new CEO to lead the charge for its can­di­date de­signed to mim­ic meta­bol­ic surgery.

Sapan Shah is tak­ing the dri­ver’s seat at Glyscend as found­ing CEO Ashish Nim­gaonkar shifts to oth­er roles as chief med­ical of­fi­cer and head of R&D, the com­pa­ny an­nounced on Tues­day. The news comes just a few months af­ter Glyscend un­veiled topline da­ta from a Phase IIa sug­gest­ing its lead can­di­date, GLY-200, helped type 2 di­a­betes pa­tients achieve sig­nif­i­cant re­duc­tions in blood glu­cose and a de­crease in body weight. The com­pa­ny hopes the oral drug will have the same ef­fects as meta­bol­ic surgery with­out the cost and com­pli­ca­tions from the in­va­sive pro­ce­dure.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER